Fig. 1 · Structure

Documents & Downloads

Marizomib (NPI-0052, salinosporamide A)

Cat. No. A13853 CAS 437742-34-2

Proteasome Inhibitor

Marizomib is a naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity.

In Stock

Publications for Marizomib

1 publication citing this product

  1. Tarantelli C, .et al. , Clin Cancer Res, 2018, Jan 1;24(1):120-129 PMID: 29066507

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Marizomib (salinosporamide A) inhibits the three catalytic activities of human 20S proteasome. In a purified-enzyme assay, β5 inhibition was more potent than β2 or β1 inhibition. Cryo-EM of the human complex showed covalent attachment to catalytic Thr1 in all three catalytic subunit types. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
HCT-116 IC50 16 nM Cytotoxicity against human HCT116 cells after 72 hrs by MTS/PMS assay [PMID: 19746976]
RPMI-8226 IC50 11 nM Cytotoxicity against human RPMI8226 cells after 48 hrs by resazurin assay [PMID: 19133779]

In Vitro Studies

Marizomib reduced viability in LN229 and U118 glioblastoma cells after 24–48 h. MTT-derived IC50 values were 217.3 and 126.9 nM for LN229 at 24 and 48 h, respectively, and 297.0 and 99.03 nM for U118. ATP-based measurements supported the viability response. [2]

In LN229 and U118 cells, 50–100 nM marizomib increased ER-stress-associated markers. The same study found no significant ROS increase and no detected increase in the assessed autophagy markers under its conditions. These observations support a model-specific stress response; they do not establish ER stress as necessary for cell death. [2]

Subunit-dependent inhibition of purified human 20S proteasome

Biochemical assay · Purified human constitutive 20S proteasome with PA28α activator [1]

Marizomib inhibited β5 most potently under this assay timing, with higher IC50 values for β2 and β1. Figure values are mean ± SD from three technical replicates, not independent biological replicates.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
β5 chymotrypsin-like proteolytic activityIC50 18.5 ± 0.8 nM[1]
β2 trypsin-like proteolytic activityIC50 326.5 ± 27.1 nM[1]
β1 caspase-like proteolytic activityIC50 596.6 ± 65.0 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–12.5 μM concentration series
Exposure duration
IC50 calculated 60–90 min after reaction initiation
Method
Subunit-selective fluorogenic activity assay at 37 °C; 1 nM h20S with 100 nM PA28α
Co-treatment
None
Reported limits
Inhibitor vehicle and enzyme–inhibitor preincubation time are not specified in the selected assay methods; substrate prefix differs between Methods and Figure 2 for β5.
Methods and source locations

Compound reported in the paper: Marizomib; Compound label in the paper: MZB

Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.

Results 2.1; Figure 2 and caption; Materials preface; Methods 4.1

β5 chymotrypsin-like proteolytic activity: LLVY-AMC fluorogenic substrate; mean ± SD, 3 technical replicates — Figure 2 labels/caption; Results 2.1; Methods 4.1

β2 trypsin-like proteolytic activity: Z-VLR-AMC fluorogenic substrate; mean ± SD, 3 technical replicates — Figure 2 labels/caption; Results 2.1; Methods 4.1

β1 caspase-like proteolytic activity: Z-LLE-AMC fluorogenic substrate; mean ± SD, 3 technical replicates — Figure 2 labels/caption; Results 2.1; Methods 4.1

Covalent binding at human proteasome catalytic sites

Biochemical assay · Marizomib-bound purified human 20S proteasome, single-particle cryo-EM [1]

The reported human 20S reconstruction places marizomib covalently attached to catalytic Thr1 at β1, β2 and β5 sites in both β-rings. This is structural evidence of covalent engagement; the experiment does not measure cellular potency or inhibitor washout kinetics.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding to β1, β2 and β5 catalytic sitesStructural observation Covalent linkage to N-terminal catalytic Thr1 in all three catalytic subunit types[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM marizomib with approximately 0.6 μM h20S
Exposure duration
1 h at room temperature before cooling
Method
Single-particle cryo-EM and model refinement
Co-treatment
None
Reported limits
No matched unbound cryo-EM sample is reported in these sections; comparison used the existing human 20S model PDB 7PG9. SI validation plots were not retrieved.
Methods and source locations

Compound reported in the paper: Marizomib; Compound label in the paper: MZB

Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.

Results 2.2–2.3; Figure 3 and caption; Materials preface; Methods 4.2–4.4

Binding to β1, β2 and β5 catalytic sites: Cryo-EM density and fitted ligand model, Figure 3B–C — Results 2.2–2.3; Figure 3B–C; Methods 4.2–4.4

Viability reduction in LN229 and U118 glioblastoma cells

Cell-based study · Human LN229 and U118 glioblastoma cell lines [2]

Marizomib reduced MTT viability and ATP-based signal after 24 or 48 h. MTT-derived IC50 values differed by cell line and exposure duration. Bortezomib and carfilzomib were separate comparators, not combinations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LN229 MTT viabilityIC50 24 h: 217.3 nM; 48 h: 126.9 nM[2]
U118 MTT viabilityIC50 24 h: 297.0 nM; 48 h: 99.03 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
5–1000 nM
Exposure duration
24 and 48 h
Method
MTT viability with complementary CellTiter-Glo ATP assay
Vehicle
DMSO stock; vehicle controls contained 0.5% DMSO; treatment DMSO reported below 1%
Co-treatment
None
Reported limits
Exact DMSO matching for each treatment concentration is not given. Figure 1 does not provide uncertainty intervals for fitted IC50 values.
Methods and source locations

Compound reported in the paper: Marizomib; Compound label in the paper: MZB

Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.

Results 2.1; Figure 1A–B, E and caption; Methods 4.1–4.4, 4.10

LN229 MTT viability: Nonlinear regression, GraphPad Prism 9; values transcribed from Figure 1E table — Figure 1E LN229 table; Results 2.1; Methods 4.2–4.4, 4.10

U118 MTT viability: Nonlinear regression, GraphPad Prism 9; values transcribed from Figure 1E table — Figure 1E U118 table; Results 2.1; Methods 4.2–4.4, 4.10

ER-stress markers with no significant measured ROS increase

Cell-based study · Human LN229 and U118 glioblastoma cell lines [2]

ER-stress markers increased, whereas measured ROS did not significantly change. ERO1α and the assessed autophagy markers did not show the increases expected for those pathways. These findings limit claims that ROS elevation or autophagy is a universal response to marizomib.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ER-stress-associated protein and transcript responsesQualitative direction Increased GRP78, IRE1α, p-EIF2α and CHOP protein; increased ATF4 and ATF6α transcripts[2]
Measured ROS and assessed autophagy markersQualitative direction No significant ROS increase; no detected increase in ERO1α, LC3 I/II, Beclin 1 or ATG5[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 and 100 nM
Exposure duration
24 h exposure; ROS method additionally specifies 6 h after substrate addition
Method
Western blot, RT-qPCR and ROS-Glo H2O2 luminescence assay
Vehicle
DMSO vehicle control: 0.5%; treatment DMSO below 1%
Co-treatment
None
Reported limits
Figure 3 labels ROS as the 24 h treatment experiment; Methods 4.7 adds a 6 h substrate-incubation step. Exact total timing and dose-specific vehicle matching are not clarified. No stress-pathway inhibition control is reported in the selected stress experiment.
Methods and source locations

Compound reported in the paper: Marizomib; Compound label in the paper: MZB

Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.

Results 2.3; Figure 3A–D and caption; Methods 4.1–4.2, 4.7–4.10; Discussion ROS/autophagy paragraphs

ER-stress-associated protein and transcript responses: Representative blots normalized by β-tubulin loading controls and RT-qPCR relative to vehicle; mean ± SD, three independent experiments run in triplicate per Methods — Figure 3A–B; Results 2.3; Methods 4.8–4.10

Measured ROS and assessed autophagy markers: ROS-Glo H2O2, representative blots and RT-qPCR; vehicle-controlled — Figure 3B–D; Results 2.3; Methods 4.7–4.10

In Vivo Studies

In an intracranial D-54 glioma xenograft model, twice-weekly intravenous marizomib at 200 µg/kg prolonged survival versus vehicle (author-reported averages: 31 versus 18 days; P < .05). The 150 µg/kg group did not show a significant survival benefit. This result is limited to the tested mouse model and regimen. [3]

Dose-dependent survival outcome in an orthotopic glioma xenograft

Animal study · Athymic BALB/c nu/nu mice bearing intracranial human D-54 glioma xenografts; randomized groups n = 6–8 [3]

Marizomib at 200 µg/kg prolonged survival relative to vehicle in this model, while 150 µg/kg did not. Survival was measured from treatment start to moribund signs requiring euthanasia; reported averages should not be relabeled medians.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Time from treatment initiation to moribund endpoint/euthanasiaAuthor-reported average survival Vehicle: 18 days; 200 µg/kg: 31 days (P < .05, log-rank); 150 µg/kg: no significant difference versus vehicle[3]

Conditions shared by the study groups

Route
Intravenous, tail vein
Frequency
Twice weekly, days 1, 4, 8, 11, 15, etc.
Treatment course
Treatment started 4 days after implantation; stopping date for survival cohort not explicitly stated.
Vehicle
Vehicle control used; formulation is not restated specifically for the xenograft survival experiment.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlVehicle-treated xenograft-bearing miceAuthor-reported average survival 18 days; neurological symptoms required euthanasia 15–22 days after treatment start.[3]
Marizomib, MTD
200 µg/kg
Vehicle-treated xenograft-bearing miceAuthor-reported average survival 31 days versus 18 days for vehicle; P < .05, log-rank test.[3]
Marizomib, MTD-1
150 µg/kg
Vehicle-treated xenograft-bearing miceSurvival was not different from vehicle control in the reported analysis.[3]
Vehicle control
Model: D-54 intracranial xenografts in athymic BALB/c nu/nu mice; groups n = 6–8
Reported limits: Exact n by arm, sex and age of survival-cohort animals are not specified in the selected xenograft methods; no complete course duration is given.
Marizomib, MTD
Model: D-54 intracranial xenografts in athymic BALB/c nu/nu mice; groups n = 6–8
Reported limits: Exact n by arm, sex and age of survival-cohort animals are not specified in the selected xenograft methods; no complete course duration is given.
Marizomib, MTD-1
Model: D-54 intracranial xenografts in athymic BALB/c nu/nu mice; groups n = 6–8
Reported limits: Exact n by arm, sex and age of survival-cohort animals are not specified in the selected xenograft methods; no complete course duration is given.
Methods and source locations

Compound reported in the paper: Marizomib; Compound label in the paper: Marizomib (NPI-0052; salinosporamide A)

Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.

Chemicals and Reagents; MTD methods for context; Intracranial Xenograft Implantation and Marizomib Treatment; xenograft Results; Figure 5B and caption

Time from treatment initiation to moribund endpoint/euthanasia: Kaplan–Meier survival analysis; n = 6–8 per group; Figure 5B — Figure 5B and caption; xenograft Results; Intracranial Xenograft Implantation and Marizomib Treatment

Vehicle control · Intracranial Xenograft Implantation and Marizomib Treatment; Figure 5B; xenograft Results

Marizomib, MTD · Intracranial Xenograft Implantation and Marizomib Treatment; Figure 5B; xenograft Results

Marizomib, MTD-1 · Intracranial Xenograft Implantation and Marizomib Treatment; Figure 5B; xenograft Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 437742-34-2
Applications Proteasome Inhibitor
Formula C15H20ClNO4
Molecular Weight 313.77
Synonyms ML 858; NPI 0052; Salinosporamide A
SMILES
C[C@]12[C@H](C(=O)N[C@]1(C(=O)O2)[C@H]([C@H]3CCCC=C3)O)CCCl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 59 mg/mL (188.02 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Sülzen H, Fajtova P, O'Donoghue AJ, et al. Structural Insights into Salinosporamide a Mediated Inhibition of the Human 20S Proteasome Molecules (Basel, Switzerland) (2025). PMID: 40142161 DOI: 10.3390/molecules30061386 Source material
  2. [2] Kusaczuk M, Tyszka N, Krętowski R, et al. The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells Pharmaceuticals (Basel, Switzerland) (2024). PMID: 39204194 DOI: 10.3390/ph17081089 Source material
  3. [3] Di K, Lloyd GK, Abraham V, et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier Neuro-oncology (2016). PMID: 26681765 DOI: 10.1093/neuonc/nov299 Source material

Publications

1 publication citing this product

  1. Tarantelli C, .et al. , Clin Cancer Res, 2018, Jan 1;24(1):120-129 PMID: 29066507

Added to your cart

View Cart Checkout
Loading...